169505-89-9 Usage
Uses
Used in Pharmaceutical Industry:
[2-(6-fluoro-1H-indol-3-yl)-1,1-dimethylethyl]amine is used as a pharmaceutical agent for its potential role in modulating serotonin receptors in the brain. This interaction may lead to the development of new treatments for various conditions related to mood, behavior, and mental health.
Used in Research and Development:
In the field of research, [2-(6-fluoro-1H-indol-3-yl)-1,1-dimethylethyl]amine is used as a research compound for studying the serotonin system and its impact on mood, behavior, and mental health. [2-(6-fluoro-1H-indol-3-yl)-1,1-dimethylethyl]amine can help scientists better understand the underlying mechanisms of these processes and potentially lead to the discovery of new therapeutic approaches.
Used in Medicinal Chemistry:
[2-(6-fluoro-1H-indol-3-yl)-1,1-dimethylethyl]amine is used as a starting material or intermediate in the synthesis of other tryptamine-based compounds with potential pharmaceutical applications. Its unique structure and properties make it a valuable tool in the development of new drugs targeting the serotonin system.
Check Digit Verification of cas no
The CAS Registry Mumber 169505-89-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,9,5,0 and 5 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 169505-89:
(8*1)+(7*6)+(6*9)+(5*5)+(4*0)+(3*5)+(2*8)+(1*9)=169
169 % 10 = 9
So 169505-89-9 is a valid CAS Registry Number.
169505-89-9Relevant academic research and scientific papers
N-ARYLOXYALKYL TRYPTAMINE ALPHA1-ADRENERGIC RECEPTOR ANTAGONISTS
-
, (2008/06/13)
The present invention relates to novel N-aryloxyalkyl tryptamine . alpha. 1-adrenergic receptor antagonists of the formula I: STR1 in which n is 2, 3 or 4; q is 1, 2 or 3; t is 0, 1, 2 or 3; z is 0, 1, 2 or 3; each R 1 and R 2 are independently hydroxy, halogen, cyano, (C 1-8)alkyl, (C 1-8)alkyloxy or trifluoromethyl; and R 2 is hydrogen, (C 1-4)alkyl, fluoro(C 1-4)alkyl, difluoro(C 1-4) alkyl, trifluoro(C 1-4)alkyl, (C 1-4) alkyloxy(C 1-4)alkyl, oxo(C 1-4)alkyl, (C 1-8)cycloalkyl, (C. sub.1-8)cycloalkylmethyl or allyl or phenyl(C 1-4)alkyl or heterocyclo(C 1-8)alkyl (optionally substituted with one to two substituents independently selected from (C 1-4)alkyl, (C 1-4) alkyloxy, trifluoromethyl and halogen); R. sup.3 and R 4 are independently hydrogen, (C 1-4) alkyl, (C 1-8)cycloalkyl, (C 1-8)cycloalkylmethyl or allyl; and R. sup. 5 is hydrogen, (C 1-4)alkyl, (C 1-8)cycloalkyl, (C 1-8) cycloalkylmethyl, allyl, (C 1-4) alkylsulfonyl and aminocarbonyl; with the proviso that when n is 2, t is 0, q is 1, z is 0, 1 or 2, R 5 is hydrogen and R 6 is hydroxy or (C 1-8)alkyloxy then at least one of R 3 and R 4 is not hydrogen; and the pharmaceutically acceptable salts, individual isomers, and mixtures of isomers thereof; their uses as therapeutic agents and the methods of their making.
